557 results about "Leiomyocyte" patented technology

Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity.

The present invention relates to engineered blood vessels and methods of making such vessels using matrices comprising endothelial and smooth muscle cells, or cells capable of differentiating into endothelial and smooth muscle cell lineages (e.g., stem cells, or the progenitors thereof).

The invention is directed to methods for preparing artificial heart valves by preconditioning a matrix seeded with endothelial cells and smooth muscle cells differentiated from isolated progenitor cells. These cell seeded matrices are exposed to fluid conditions that mimic blood flow through the heart to produce tissue engineered heart valves that are analogous to native heart valves.

A method of forming a tissue equivalent is described. A length of polyester tube is threaded over a mandrel (H) and attached at either end by clips at A and D. A block (F) is then screwed into place. The polyester is then pre-soaked by injecting through Tap (2) an acidified collagen solution for approximately one hour. After a suitable period of time the excess solution is aspirated off. Following this stage, a second, alkaline solution is injected into the apparatus which contains smooth muscle cells (SMC). Thus, neutralisation of the collagen impregnated within the fabric of the tube occurs leading to spontaneous fibrillogenesis within the interstices of the cloth, eliminating the risk of delamination. The apparatus is then incubated. The collagen contracts down onto the fabric tube and the cell-impregnated gel becomes incorporated into the presoaked collagen. The pre-impregnated collagen and the collagen provided in the aqueous mixture contract down as one into a coherent whole with the SMC. The tissue equivalent is then lined with endothelial cells and the apparatus again incubated and fed at increasing intraluminal pressures applied either statically or dynamically. This is believed to cause the vessel to become preconditioned to the pressure it will work under as an implant. This allows organization of the basement membrane which in turn promotes EC attachment and theoretically prevents smooth muscle cell hyperplasia.

The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.

The present invention provides a P2Y₁₂ receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y₁₂ receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y₁₂ receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y₁₂ receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.

In embodiments of the present invention, a biodegradable/biodegradable polymer film may be used as a scaffold for tissue engineering scaffolds for engineering organized organs, such as vascular grafts, for example. In one embodiment, an ultraviolet (UV) resin made from a diacrylated biodegradable oligomer is molded into a flexible scaffold having cavities and/or channels. Channel/cavity size may be on the order of micrometers and/or nanometers, and thus the walls may have high aspect ratios. Smooth muscle cells may be deposited in the channels and because of the high aspect ratios, the cells may align along the channels/cavities as confluence is reached.

The invention is a tissue engineered blood vessel (TEBV) made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding. The TEBV is made in a bioreactor having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling.

Described herein are engineered multilayered vascular tubes comprising at least one layer of differentiated adult fibroblasts, at least one layer of differentiated adult smooth muscle cells, wherein any layer further comprises differentiated adult endothelial cells, wherein said tubes have the following features: (a) a ratio of endothelial cells to smooth muscle cells of about 1:99 to about 45:55; (b) the tube is compliant; (c) the internal diameter of the tube is about 6 mm or smaller; (d) the length of the tube is up to about 30 cm; and (e) the thickness of the tube is substantially uniform along a region of the tube; provided that the engineered multilayered vascular tube is free of any pre-formed scaffold. Also described herein are methods of forming said tubes and uses for said tubes including methods for treating patients, comprising providing such a tube into to a patient in need thereof.

A polymeric biomaterial that facilitates cell-specific ingrowth. The polymeric biomaterial encourages the ingrowth of cell types while reducing the ingrowth of undesirable cell types. This activity encourages proper integration of prosthetic implants or scaffolds utilizing this biomaterial by discouraging encapsulation or the accumulation of inflammatory cells such as macrophages, while encouraging infiltration by desirable cells such as endothelial or smooth muscle cells. Short peptide sequences are included in a polymeric biomaterial that result in complementary activities. Peptide sequences that are specifically cleaved by proteases found within preferred cells are used to cross-link the biomaterial and lead to degradation by those cells. Peptide sequences taken from proteins involved in cell adhesion can also be attached to the biomaterial to encourage adhesion by preferred cells. Combined use of both peptides in the polymeric biomaterial provides both specific adhesion and selective ingrowth.

The invention discloses a bionic vascularized soft tissue with a multilayer vascular structure and a preparation method thereof. The preparation method comprises the steps of: employing a moulding process or 3D printing way to obtain a sacrificial membrane with a branched structure; coating or spraying a polymer solution containing a pore-foaming agent on the surface of the sacrificial membrane toobtain a polymer film; removing the treated sacrificial membrane of the structure and the pore-foaming agent to obtain a vascular channel-like structure with surface pores; conducting perfusion planting of endothelial cells in the channel of the vascular channel-like structure; planting smooth muscle cells or fibroblasts in the surface pores of the vascular channel-like structure; and placing thetreated vascular channel-like structure in a mold, adding an aquogel solution containing parenchymal cells, and conducting moulding so as to obtain the bionic vascularized soft tissue. The method provided by the invention can construct bionic blood vessels with a multilayer structure in artificial tissues.

The present invention relates generally to a drug eluting stent containing metallic surfaces modified in microsphere metallic matrix structure and methods for making same. More specifically, the invention relates to an expandable and implantable vascular stent having at least one matrix layer that promotes improved cellular adhesion properties for healing promotion healing and long term biocompatibility. In the case of coronary stents, the metallic matrix layer promotes re-endothelialization at sites of stent implantation, improves overall healing, and reduces inflammation and intimal disease progression. The microsphere metallic matrix layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy and safety. The active compounds are selected primarily for their anti-proliferative, immunosuppressive, and anti-inflammatory activities, among other properties, which prevent, in part, smooth muscle cell proliferation and promote endothelial cell growth.

The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.

The present invention relates to preparation of biological artificial blood vessel capable of in vivo capturing endothelial ancestral cell, and features that the biological artificial blood vessel may be prepared with composite blood vessel material or homogeneous or heterogeneous blood vessel with the antigen eliminated and through surface modification. The biological artificial blood vessel may be used as tissue engineering blood vessel rack, on which smooth muscle cell and/or endothelial cell may be planted. The biological artificial blood vessel of the present invention has excellent mechanical performance and anticoagulant property, and may be in different calibers. It may be in vivo reshaped and in vivo induced to plant endothelial ancestral cell. It can antagonize intravascular thrombogenesis and inhibit the pathological proliferation of smooth muscle cell to avoid angiostenosis and blood vessel blocking.

A well-based flow system for cell culture is described which provides for flow of culture containing compounds for drug screening to be exposed to cells seeded on a membrane. The flow of medium may be planar or radial and means are provided for the removal of waste media through fluid outlets in fluid communication with the assay well plates through conduits. Methods of using the system for cell culture and drug toxicity screening are also provided including coculturing cells such as hepatocytes, stem cells, fibroblasts and smooth muscle cells and selectively exposing cells to test compounds.

The invention relates to a preparation method of a shell core fiber covered endovascular stent graft. The steps are as follows: firstly, a polymer is dissolved in adaptive dissolvent to obtain solution with a certain concentration; secondly, medicine or an artificial polymer and medicine, and a bio-active element are dissolved in the adaptive dissolvent to obtain solution or suspension liquid; thirdly, the solution of the polymer and the medicine or the solution or suspension liquid of the medicine or bio-active element are respectively filled in two injectors, the speed of a micro injection pump, the voltage of an electrostatic generator and the distance of a receiving device are adjusted, fiber is obtained through the static spinning preparation, and the fiber is received as a tube shape or film shape structure; fourthly, the endovascular stent graft is fixed on a revolution axle, through the revolution of the endovascular stent graft, the static spinning fiber are directly received as fibrous membrane covered on the endovascular stent graft. The invention can effectively prevent smooth muscle cells from hyperplasia in the stent graft or from narrowing in the stent graft caused by the other functions, and the shell core fiber for the medicine loading can slowly release the medicine to attain the purpose of curing.

The invention relates to a preparation method of compound artificial blood vessel support by electrostatic textile and weave technology, which can be described as follows: 6% to 10% (g/ml) polymer spinning solution is prepared; under the control of electrostatic spinning parameter, the prepared solution is used to make nano fiber with electrostatic textile technology; the nano fiber is collected by a roller collecting device to be the inner layer of a tubular support; the fiber materials are woven into tubular form by making use of the textile equipment to be the outer layer of the tubular support; the electrostatically textile inner layer and the woven outer layer are compounded together with the method of hot shaping or coating; with the adoption of biocompatible implant technology, human endothelial cells are implanted on the inner layer of the support and human smooth muscle cells are implanted on the outer layer of the support; after cell culture, the blood support is completed. The preparation method of compound artificial blood vessel support through electrostatic textile and weave technology has the advantages of simplification and time-saving effect, fine growth activity of the prepared artificial blood vessel after being implanted into human body; besides, the smooth muscle can grow along and into the fiber, and adaptability adjustment can be made to the blood vessel according to the condition of the host, leaving less liability for embolization.

The present invention provides an in vitro blood vessel model for investigation of drug induced vascular injury and other vascular pathologies. The in vitro blood vessel model provides two channels separated by a porous membrane that is coated on one side by an endothelial cell layer and is coated on the other side by a smooth muscle cell layer, wherein said model is susceptible to the extravasation of red blood cells across said porous membrane due to drug induced vascular injury.

Restenosis of blood vessels after angioplasty is achieved by preventing of cell proliferation, particularly of smooth muscle cells, in blood vessel walls by inhibiting the ubiquitin-proteasome protein degradation pathway. The inhibition is accomplished by administering to the cells in the blood vessel walls a compound, e.g., a protein or small molecule, capable of inhibiting the ubiquitin-proteasome protein degradation pathway. The inhibiting compound is preferably administered by coating the compound on a stent and implanting the stent in the blood vessel after angioplasty.

Disclosed are a pharmaceutical composition for inhibiting vascular smooth muscle cell proliferation comprising dimethyl fumarate as an effective ingredient, use of dimethyl fumarate for inhibiting vascular smooth muscle cell proliferation, and a method of inhibiting vascular smooth muscle cell proliferation employing the same. Through the present invention, it was found that dimethyl fumarate could inhibit vascular smooth muscle cell proliferation by increasing the activity of AMPK. Accordingly, dimethyl fumarate can be usefully used as an effective ingredient of a medicine for inhibiting vascular smooth muscle cell proliferation.